SU1512473A3 - Способ получени белков с мол.м. 32000-34000, подавл ющих свертывание крови - Google Patents
Способ получени белков с мол.м. 32000-34000, подавл ющих свертывание крови Download PDFInfo
- Publication number
- SU1512473A3 SU1512473A3 SU853957808A SU3957808A SU1512473A3 SU 1512473 A3 SU1512473 A3 SU 1512473A3 SU 853957808 A SU853957808 A SU 853957808A SU 3957808 A SU3957808 A SU 3957808A SU 1512473 A3 SU1512473 A3 SU 1512473A3
- Authority
- SU
- USSR - Soviet Union
- Prior art keywords
- mmol
- dialysis
- chromatography
- tbs
- target product
- Prior art date
Links
- 102000004169 proteins and genes Human genes 0.000 title claims abstract description 18
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 18
- 238000000034 method Methods 0.000 title claims abstract description 9
- 230000023555 blood coagulation Effects 0.000 title claims description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims abstract description 56
- 239000011780 sodium chloride Substances 0.000 claims abstract description 28
- 239000007983 Tris buffer Substances 0.000 claims abstract description 19
- 238000000746 purification Methods 0.000 claims abstract description 15
- 238000004587 chromatography analysis Methods 0.000 claims abstract description 14
- 238000000502 dialysis Methods 0.000 claims abstract description 14
- PXXJHWLDUBFPOL-UHFFFAOYSA-N benzamidine Chemical compound NC(=N)C1=CC=CC=C1 PXXJHWLDUBFPOL-UHFFFAOYSA-N 0.000 claims abstract description 12
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 claims abstract description 10
- 229910052921 ammonium sulfate Inorganic materials 0.000 claims abstract description 10
- 235000011130 ammonium sulphate Nutrition 0.000 claims abstract description 10
- 229910052588 hydroxylapatite Inorganic materials 0.000 claims abstract description 9
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 claims abstract description 9
- 238000002523 gelfiltration Methods 0.000 claims abstract description 8
- 101710162629 Trypsin inhibitor Proteins 0.000 claims abstract description 7
- 229940122618 Trypsin inhibitor Drugs 0.000 claims abstract description 7
- 238000004255 ion exchange chromatography Methods 0.000 claims abstract description 7
- 239000012528 membrane Substances 0.000 claims abstract description 7
- 239000000243 solution Substances 0.000 claims abstract description 7
- 239000002753 trypsin inhibitor Substances 0.000 claims abstract description 7
- 244000068988 Glycine max Species 0.000 claims abstract description 6
- 235000010469 Glycine max Nutrition 0.000 claims abstract description 6
- 229920005654 Sephadex Polymers 0.000 claims abstract description 6
- 239000012507 Sephadex™ Substances 0.000 claims abstract description 6
- 238000000108 ultra-filtration Methods 0.000 claims abstract description 5
- 238000005185 salting out Methods 0.000 claims abstract description 3
- 210000000709 aorta Anatomy 0.000 claims description 9
- 238000001556 precipitation Methods 0.000 claims description 4
- 230000000740 bleeding effect Effects 0.000 claims description 3
- 239000003957 anion exchange resin Substances 0.000 claims description 2
- 238000010612 desalination reaction Methods 0.000 claims 1
- 238000000265 homogenisation Methods 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 239000002994 raw material Substances 0.000 claims 1
- 235000014347 soups Nutrition 0.000 claims 1
- UEUXEKPTXMALOB-UHFFFAOYSA-J tetrasodium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O UEUXEKPTXMALOB-UHFFFAOYSA-J 0.000 claims 1
- 239000000047 product Substances 0.000 abstract description 9
- 239000006228 supernatant Substances 0.000 abstract description 8
- 239000002244 precipitate Substances 0.000 abstract description 6
- 102000004411 Antithrombin III Human genes 0.000 abstract description 3
- 108090000935 Antithrombin III Proteins 0.000 abstract description 3
- 229960005348 antithrombin iii Drugs 0.000 abstract description 3
- 239000008280 blood Substances 0.000 abstract description 3
- 210000004369 blood Anatomy 0.000 abstract description 3
- 239000003114 blood coagulation factor Substances 0.000 abstract description 3
- 150000001450 anions Chemical class 0.000 abstract description 2
- 238000005119 centrifugation Methods 0.000 abstract description 2
- -1 diethylaminoethyl groups Chemical group 0.000 abstract description 2
- 239000003814 drug Substances 0.000 abstract description 2
- 210000005166 vasculature Anatomy 0.000 abstract description 2
- 102000015081 Blood Coagulation Factors Human genes 0.000 abstract 1
- 108010039209 Blood Coagulation Factors Proteins 0.000 abstract 1
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 abstract 1
- 206010062713 Haemorrhagic diathesis Diseases 0.000 abstract 1
- 208000031169 hemorrhagic disease Diseases 0.000 abstract 1
- NQMRYBIKMRVZLB-UHFFFAOYSA-N methylamine hydrochloride Chemical compound [Cl-].[NH3+]C NQMRYBIKMRVZLB-UHFFFAOYSA-N 0.000 abstract 1
- 239000000872 buffer Substances 0.000 description 17
- 230000000694 effects Effects 0.000 description 16
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 12
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerol Natural products OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 239000012064 sodium phosphate buffer Substances 0.000 description 6
- 238000011067 equilibration Methods 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 241000283690 Bos taurus Species 0.000 description 4
- OWMVSZAMULFTJU-UHFFFAOYSA-N bis-tris Chemical compound OCCN(CCO)C(CO)(CO)CO OWMVSZAMULFTJU-UHFFFAOYSA-N 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
- 239000001166 ammonium sulphate Substances 0.000 description 3
- 230000015271 coagulation Effects 0.000 description 3
- 238000005345 coagulation Methods 0.000 description 3
- 235000011187 glycerol Nutrition 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 150000003904 phospholipids Chemical class 0.000 description 3
- PGOHTUIFYSHAQG-LJSDBVFPSA-N (2S)-6-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-1-[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-4-methylsulfanylbutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]propanoyl]pyrrolidine-2-carbonyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]-4-methylpentanoyl]amino]-3-sulfanylpropanoyl]amino]-4-methylsulfanylbutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-hydroxybutanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-hydroxypropanoyl]amino]-3-hydroxypropanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxybutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-oxopentanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-3-carboxypropanoyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-oxopentanoyl]amino]-3-phenylpropanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-oxobutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-4-carboxybutanoyl]amino]-5-oxopentanoyl]amino]hexanoic acid Chemical compound CSCC[C@H](N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(O)=O PGOHTUIFYSHAQG-LJSDBVFPSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 108010000499 Thromboplastin Proteins 0.000 description 2
- 102000002262 Thromboplastin Human genes 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 239000003146 anticoagulant agent Substances 0.000 description 2
- 229940127219 anticoagulant drug Drugs 0.000 description 2
- 239000002506 anticoagulant protein Substances 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 229920002401 polyacrylamide Polymers 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 238000003307 slaughter Methods 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- QIVUCLWGARAQIO-OLIXTKCUSA-N (3s)-n-[(3s,5s,6r)-6-methyl-2-oxo-1-(2,2,2-trifluoroethyl)-5-(2,3,6-trifluorophenyl)piperidin-3-yl]-2-oxospiro[1h-pyrrolo[2,3-b]pyridine-3,6'-5,7-dihydrocyclopenta[b]pyridine]-3'-carboxamide Chemical compound C1([C@H]2[C@H](N(C(=O)[C@@H](NC(=O)C=3C=C4C[C@]5(CC4=NC=3)C3=CC=CN=C3NC5=O)C2)CC(F)(F)F)C)=C(F)C=CC(F)=C1F QIVUCLWGARAQIO-OLIXTKCUSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- 108010014173 Factor X Proteins 0.000 description 1
- 108010074860 Factor Xa Proteins 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 108010067372 Pancreatic elastase Proteins 0.000 description 1
- 102000016387 Pancreatic elastase Human genes 0.000 description 1
- 244000046052 Phaseolus vulgaris Species 0.000 description 1
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 1
- 108010094028 Prothrombin Proteins 0.000 description 1
- 102100027378 Prothrombin Human genes 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 108090000190 Thrombin Proteins 0.000 description 1
- 238000005903 acid hydrolysis reaction Methods 0.000 description 1
- 150000001409 amidines Chemical class 0.000 description 1
- 230000003024 amidolytic effect Effects 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- 229910052804 chromium Inorganic materials 0.000 description 1
- 239000011651 chromium Substances 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 239000013065 commercial product Substances 0.000 description 1
- 239000013068 control sample Substances 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 229940071106 ethylenediaminetetraacetate Drugs 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 238000001155 isoelectric focusing Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000014508 negative regulation of coagulation Effects 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 229940039716 prothrombin Drugs 0.000 description 1
- 238000009738 saturating Methods 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 229960004072 thrombin Drugs 0.000 description 1
- 210000003954 umbilical cord Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/44—Vessels; Vascular smooth muscle cells; Endothelial cells; Endothelial progenitor cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Cell Biology (AREA)
- Vascular Medicine (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Developmental Biology & Embryology (AREA)
- Immunology (AREA)
- Virology (AREA)
- Zoology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| NL8402904A NL8402904A (nl) | 1984-09-21 | 1984-09-21 | De bloedstolling remmend eiwitmateriaal, werkwijze voor het isoleren daarvan alsmede farmaceutisch preparaat. |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SU1512473A3 true SU1512473A3 (ru) | 1989-09-30 |
Family
ID=19844504
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SU853957808A SU1512473A3 (ru) | 1984-09-21 | 1985-09-20 | Способ получени белков с мол.м. 32000-34000, подавл ющих свертывание крови |
Country Status (5)
| Country | Link |
|---|---|
| DD (1) | DD241691A5 (enrdf_load_stackoverflow) |
| GR (1) | GR852300B (enrdf_load_stackoverflow) |
| NL (1) | NL8402904A (enrdf_load_stackoverflow) |
| SU (1) | SU1512473A3 (enrdf_load_stackoverflow) |
| ZA (1) | ZA857222B (enrdf_load_stackoverflow) |
-
1984
- 1984-09-21 NL NL8402904A patent/NL8402904A/nl not_active Application Discontinuation
-
1985
- 1985-09-18 DD DD85280751A patent/DD241691A5/de not_active IP Right Cessation
- 1985-09-20 GR GR852300A patent/GR852300B/el unknown
- 1985-09-20 ZA ZA857222A patent/ZA857222B/xx unknown
- 1985-09-20 SU SU853957808A patent/SU1512473A3/ru active
Non-Patent Citations (1)
| Title |
|---|
| Нао J.L. et al, Methods of Plasma Protein Fractionation. /Ed.J.M.Cur- ling, London ete: Academie Press, 1980, p. 62-64. * |
Also Published As
| Publication number | Publication date |
|---|---|
| DD241691A5 (de) | 1986-12-24 |
| ZA857222B (en) | 1987-05-27 |
| NL8402904A (nl) | 1986-04-16 |
| GR852300B (enrdf_load_stackoverflow) | 1986-01-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5066787A (en) | Blood coagulation inhibiting proteins, processes for preparing them and their uses | |
| FI106721B (fi) | Menetelmä ihmisen standardisoidun, korkean puhtauden omaavan von Willebrand -tekijän konsentraatin valmistamiseksi | |
| FI95136C (fi) | Menetelmä anneksiinien puhdistamiseksi | |
| US6261803B1 (en) | Process for preparing functional recombinant tissue factor | |
| JPH0386900A (ja) | 新規なトロンビン結合性物質及びその製法 | |
| US5066788A (en) | Blood coagulation inhibiting proteins, processes for preparing them and their uses | |
| Esnard et al. | Partial characterization of a fibrinolytic inhibitor produced by cultured endothelial cells derived from human umbilical vein | |
| SU1512473A3 (ru) | Способ получени белков с мол.м. 32000-34000, подавл ющих свертывание крови | |
| JPH01502667A (ja) | 抗凝固活性及び抗炎症活性を有するヒト蛋白質 | |
| US6869934B2 (en) | Method of purifying calcium ion-binding protein | |
| EP0229026B1 (en) | Therapeutic blood product, means and methods of preparing same | |
| US5047503A (en) | Thrombin-binding substance and process for its preparation | |
| JPH0472840B2 (enrdf_load_stackoverflow) | ||
| Borsodi et al. | Isolation of Antithrombin III from Normal and α1-Antitrypsin-Deficient Human Plasma | |
| RU2337966C2 (ru) | Препарат рекомбинантного человеческого сывороточного альбумина и способ его получения | |
| Smariga et al. | Purification of a platelet protein which stimulates fibrinolytic inhibition and tissue factor in human fibroblasts. | |
| EP0112940B1 (en) | Method of producing a tissue plasminogen activator and composition comprising same | |
| EP0042560A2 (en) | A process for producing and obtaining anaphylatoxin- and cocytotaxin-containing leucotaxine preparations and of anaphylatoxin and cocytotaxin proteins in molecularly homogeneous, biologically active form | |
| RU2225722C1 (ru) | Способ получения человеческого интерферона | |
| KR100256040B1 (ko) | 토끼 프로트롬빈 크링글-2 단백질 및 그의 정제방법 | |
| Chung et al. | Partial purification of a vasoactive protein in guinea pig skin | |
| Kopitar et al. | Biochemical and Biological Characteristics of Leucocyte Proteinase Inhibitors | |
| JPH0393798A (ja) | プラスミノゲン活性化因子阻害剤２（ｐａｉ―２）の精製方法 | |
| KR20020008471A (ko) | 내피세포 성장 억제활성을 가지는 인간 프로트롬빈크링글, 그것의 재조합벡터 및 이를 발현하는 재조합 숙주 | |
| KOPITAR | Subcellular pattern of leucocyte proteinase inhibitors Cell homogenate (0.34 M sucrose) |